This post was originally published on this site Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free survival times than those given chemotherapy, full results from the SOLO-3 Phase 3 trial show. These findings make…
Conditions
Conditions
Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives
This post was originally published on this site Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate cancer, a Phase 3 trial shows. The findings — which supported Janssen’s application to the U.S. Food and…
Alzheimer’s Diagnostics Accelerator Program Awards Nearly $3.5M to Develop Early-detection Methods
This post was originally published on this site Selected through the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator program, four scientists will share nearly $3.5 million to develop new biomarkers for early detection of Alzheimer’s disease and related dementia. Philanthropists, including ADDF co-founder Leonard Lauder, Bill Gates and Jeff and MacKenzie Bezos, are expected to fund $10…
New AI-based Model Outperforms Current Methods of Predicting Breast Cancer Risk
This post was originally published on this site Scientists have created a new artificial intelligence (AI)-based model that outperforms current models at predicting the risks a woman has of developing breast cancer, and works equally well in white and African American women. The findings of the study, “A Deep Learning Mammography-based Model for Improved Breast…
Kite’s Investigational CAR-T Cell Therapy Shows Promise in Phase 1/2 Trial
This post was originally published on this site A single infusion of KTE-X19, Kite Pharma‘s investigational CD19 CAR-T cell therapy, leads to high response rates in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), Phase 1/2 trial data show. The findings were presented during an oral session titled, “End of phase I results of…
Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows
This post was originally published on this site Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic hormone-sensitive prostate cancer in comparison with standard of care, according to early findings of a large Phase 3 trial. The study, “Overall survival (OS) results of a phase III randomized trial of standard-of-care…
Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals
This post was originally published on this site Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, updated Phase 3 data shows. Three-year data from the company’s randomized, open-label ECHELON-1 Phase 3 trial (NCT01712490) was…
Similar Efficacy and Safety Seen Between Under-the-Skin Formulation and Intravenous Darzalex for Myeloma, Phase 3 Trial Shows
This post was originally published on this site An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable safety in adults with relapsed or refractory multiple myeloma, according to a Phase 3 trial. Trial results were presented in a study, “Efficacy…
Immune Checkpoint Molecules Have Prognostic Value in Ovarian Cancer, Study Reports
This post was originally published on this site The immune checkpoint molecules PD-L1 and TIM-3 have prognostic value in people with ovarian cancer who have not yet received chemotherapy. But while low levels of TIM-3 were linked to longer survival rates, a study unexpectedly showed that high levels of PD-L1 predicted better patient survival. The…
ProMIS’ PMN310 Antibody Candidate Shows Greater Effect, Less Risk Than Other Therapies, According to Data
This post was originally published on this site ProMIS Neurosciences’ candidate PMN310 can specifically target toxic clusters of soluble amyloid-beta protein, and be safely administered at high doses with reduced risk of characteristic Alzheimer’s brain changes or swelling, according to clinical data. PMN310 has the potential for greater therapeutic potency compared with other amyloid-beta-directed antibodies…
Mourning Is a Natural Process for Caregivers
This post was originally published on this site We tend to categorize loss. The loss of a child is the pinnacle of grief. That’s understandable. The loss of a parent is also devastating. However, it wasn’t until my mother received her dementia diagnosis that I genuinely understood that loss doesn’t always involve finality. Dementia isn’t…
Long-term Data Continue to Support Perjeta Regimen for HER2-positive Metastatic Breast Cancer
This post was originally published on this site End-of-study data from the CLEOPATRA trial supports the long-term efficacy of Genentech‘s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy for patients with previously untreated HER2-positive metastatic breast cancer. Patients on the Perjeta combination regimen lived a median 16.3 months longer, compared with the control group not receiving Perjeta,…